Key result
This review outlines currently available antiplatelet treatments for STEMI patients undergoing primary PCI, focusing on therapeutic timelines and challenges like acute stent thrombosis and morphine.
This review summarizes contemporary antiplatelet strategies for STEMI patients undergoing primary PCI, highlighting challenges such as acute stent thrombosis and the impact of morphine on platelet inhibition.
Alerts clinicians to morphine effects on antiplatelet response in STEMI PCI; leaves open optimal strategies to reduce stent thrombosis.
Reperfusion therapy for patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) involves primary percutaneous coronary intervention (PPCI) and concomitant oral antiplatelet and intravenous antithrombotic pharmacotherapy. There is a conflict between the desire to reduce the time between first medical contact and coronary re-canalisation and achieving effective platelet inhibition with oral antiplatelet agents. This review outlines the currently available antiplatelet treatments, and their place within the therapeutic timeline of a patient presenting with STEMI. Additionally, we focus on current challenges associated with effective antiplatelet treatment, including acute stent thrombosis (AST), the effect of morphine, platelet function assessment and concomitant anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Kandan et al. (2015) conducted a review in ST-segment elevation myocardial infarction (STEMI). Antiplatelet treatments was evaluated. This review outlines currently available antiplatelet treatments for STEMI patients undergoing primary PCI, focusing on therapeutic timelines and challenges like acute stent thrombosis and morphine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: